Continuing Dismay In Alzheimer's: vTv's RAGE Antagonist Fails In Phase III Study
A further mechanism of action has proven ineffective in top-line data from a late-stage study in Alzheimer's disease, adding to the long list of tried and failed approaches to the seemingly intractable condition.
You may also be interested in...
Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed
Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.
Boehringer Shoots For Schizophrenia With PDE9 Inhibitor, Ends Alzheimer's R&D
Boehringer's investigational drug, BI 409306, is the second big pharma PDE9 inhibitor to fail in Alzheimer's clinical trials; Eisai is still standing with a Phase I compound but the odds are not in its favor.